Showing 1 - 15 results of 15 for search 'Francesco Gelsomino', query time: 0.05s Refine Results
  1. 1
    MET and Small-Cell Lung Cancer

    MET and Small-Cell Lung Cancer by Francesco Gelsomino, Giulio Rossi, Marcello Tiseo

    Published 2014-10-01
    Get full text
    Article
  2. 2
    Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence

    Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence by Karim Rihawi, Francesco Gelsomino, Francesca Sperandi, Barbara Melotti, Michelangelo Fiorentino, Laura Casolari, Andrea Ardizzoni

    Published 2017-09-01
    Get full text
    Article
  3. 3
    Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)

    Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) by Andrea De Giglio, Marta Aprile, Alessandro Di Federico, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino, Andrea Ardizzoni

    Published 2022-09-01
    Get full text
    Article
  4. 4
    The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?

    The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players? by Giuseppe Lamberti, Monia Sisi, Elisa Andrini, Arianna Palladini, Francesca Giunchi, Pier-Luigi Lollini, Andrea Ardizzoni, Francesco Gelsomino

    Published 2020-10-01
    Get full text
    Article
  5. 5
    From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)

    From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC) by Laura Fabbri, Alessandro Di Federico, Martina Astore, Virginia Marchiori, Agnese Rejtano, Renata Seminerio, Francesco Gelsomino, Andrea De Giglio

    Published 2023-12-01
    Get full text
    Article
  6. 6
    IFN-γ and CD38 in Hyperprogressive Cancer Development

    IFN-γ and CD38 in Hyperprogressive Cancer Development by Stefania Angelicola, Francesca Ruzzi, Lorena Landuzzi, Laura Scalambra, Francesco Gelsomino, Andrea Ardizzoni, Patrizia Nanni, Pier-Luigi Lollini, Arianna Palladini

    Published 2021-01-01
    Get full text
    Article
  7. 7
    New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event

    New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event by Giuseppe Lamberti, Francesco Gelsomino, Stefano Brocchi, Antonio Poerio, Barbara Melotti, Francesca Sperandi, Mauro Gargiulo, Claudio Borghi, Michelangelo Fiorentino, Andrea Ardizzoni

    Published 2020-07-01
    Get full text
    Article
  8. 8
    Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis

    Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Revi... by Alessandro Di Federico, MD, Andrea De Giglio, MD, Claudia Parisi, MD, Francesco Gelsomino, MD, Luca Boni, MD, Andrea Ardizzoni, Prof

    Published 2021-09-01
    Get full text
    Article
  9. 9
    Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring <i>BRAF</i> Alterations of Distinct Functional Classes

    Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring <i>BRAF</i> Alterations of Distinct Functional Classes by Alessandro Di Federico, Andrea De Giglio, Francesco Gelsomino, Dario De Biase, Francesca Giunchi, Arianna Palladini, Francesca Sperandi, Barbara Melotti, Andrea Ardizzoni

    Published 2022-07-01
    Get full text
    Article
  10. 10
    The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy

    The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy by Andrea De Giglio, Elisa Tassinari, Arianna Zappi, Alessandro Di Federico, Barbara Lenzi, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino, Marco Maltoni, Andrea Ardizzoni

    Published 2022-11-01
    Get full text
    Article
  11. 11
    Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches

    Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches by Noemi Laprovitera, Noemi Laprovitera, Irene Salamon, Irene Salamon, Francesco Gelsomino, Francesco Gelsomino, Elisa Porcellini, Mattia Riefolo, Mattia Riefolo, Marianna Garonzi, Paola Tononi, Sabrina Valente, Silvia Sabbioni, Francesca Fontana, Nicolò Manaresi, Antonia D’Errico, Antonia D’Errico, Maria A. Pantaleo, Maria A. Pantaleo, Andrea Ardizzoni, Andrea Ardizzoni, Manuela Ferracin

    Published 2021-06-01
    Get full text
    Article
  12. 12
    Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors

    Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors by Monia Sisi, MD, Giovanni Vitale, MD, PhD, Michele Fusaroli, MD, Mattia Riefolo, MD, Valentina Giunchi, BSc, Antonietta D’Errico, MD, Andrea Ardizzoni, MD, Emanuel Raschi, MD, PhD, Francesco Gelsomino, MD

    Published 2023-09-01
    Get full text
    Article
  13. 13
    Atezolizumab in a oort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal Subtyps (CHANCE trial)

    Atezolizumab in a oort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal Subtyps (CHANCE trial) by Francesco Gelsomino, Giuseppe Lamberti, Marcello Tiseo, Danilo Rocco, Giulia Pasello, Fabiana Letizia Cecere, Antonio Chella, Giada Grilli, Marcella Mandruzzato, Michele Tognetto, Marina Chiara Garassino, Marianna Macerelli, Silvia Novello, Fausto Roila, Ida Colantonio, Francesco Grossi, Michelangelo Fiorentino, Andrea Ardizzoni

    Published 2020-07-01
    Get full text
    Article
  14. 14
    Genetic and Functional Characterization of Toll-Like Receptor Responses in Immunocompetent Patients With CMV Mononucleosis

    Genetic and Functional Characterization of Toll-Like Receptor Responses in Immunocompetent Patients With CMV Mononucleosis by Giada Frascaroli, Giada Rossini, Virginia Maltoni, Michele Bartoletti, Patrizia Ortolani, Sara Gredmark-Russ, Sara Gredmark-Russ, Francesco Gelsomino, Alessandra Moroni, Silvia Silenzi, Gastone Castellani, Vittorio Sambri, Vittorio Sambri, Antonio Mastroianni, Antonio Mastroianni, Wolfram Brune, Stefania Varani, Stefania Varani

    Published 2020-08-01
    Get full text
    Article
  15. 15
    Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

    Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer by Lorenza Landi, Federica D’Incà, Alain Gelibter, Rita Chiari, Francesco Grossi, Angelo Delmonte, Antonio Passaro, Diego Signorelli, Francesco Gelsomino, Domenico Galetta, Diana Giannarelli, Hector Soto Parra, Gabriele Minuti, Marcello Tiseo, Maria Rita Migliorino, Francesco Cognetti, Luca Toschi, Paolo Bidoli, Francovito Piantedosi, Luana Calabro’, Federico Cappuzzo

    Published 2019-11-01
    Get full text
    Article

Search Tools: